Compare Ascendis Pharma A/S (ASND) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Avantis International Small Cap Value ETF — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while Avantis International Small Cap Value ETF trades at $103.01. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Avantis International Small Cap Value ETF nearer its low. Which is the better fit depends on your goals.
| ASND | AVDV | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $110.40 |
52-Week Low | $163.32 | $80.02 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
AVDV trades at $104.2, up 1.04% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF focuses on international small-cap value stocks from developed markets, offering diversification and a modest dividend, with a $1.39 dividend scheduled for June 2026. Recent news highlights its 35% gains in 2026, outperforming the S&P 500 by 5.7%, though some analysts express caution about cyclical reliance.
The outlook is mixed: strong recent performance and institutional interest support upside, but bearish technicals and concerns over structural alpha pose risks. Investors should weigh the ETF's value approach against potential volatility from international markets and sector cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →
